Mark Barakat, MD: Stable IOP Outcomes After Aflibercept 8 mg in DME
Pre-dose IOP outcomes in eyes with DME receiving intravitreal aflibercept 8 mg or 2 mg were comparable and remained stable through Week 48.
Source: hcplive.com
Mark Barakat News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Mark Barakat. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Mark Barakat Today - Breaking & Trending Today
VenoStent Enrolls First Subjects in 200-Subject US Clinical Trial
VenoStent Enrolls First Subjects in 200-Subject US Clinical Trial
Source: pr-inside.com
Mark R. Barakat, MD: RGX-314 for Diabetic Retinopathy in ALTITUDE Study
First-year results from ALTITUDE suggest RGX-314 was well-tolerated and provided meaningful improvements in disease severity at dose levels 1 and 2.
Source: hcplive.com
REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
ABBV-RGX-314 continues to be well tolerated in 50 patients from dose levels 1 and 2 (Cohorts 1-3) with no drug-related serious adverse events Dose level 2...
Source: prnewswire.com
Patient Communication and Shared Decision Making
Mark Barakat, MD, reviews the best practices for patient communication and shared decision making.
Source: hcplive.com